TCR2 Therapeutics (TCRR) Receives a Hold From Mizuho Securities
TipRanksMay 11, 2023 08:45 ET
TCR2 Therapeutics (TCRR) Was Downgraded to a Hold Rating at Mizuho Securities
TipRanksMar 23, 2023 17:46 ET
Wedbush Adjusts TCR2 Therapeutics Price Target to $1.68 From $2.18, Maintains Neutral Rating
MT NewswiresMar 23, 2023 12:36 ET
Analysts Offer Insights on Healthcare Companies: TCR2 Therapeutics (TCRR) and Inozyme Pharma (INZY)
TipRanksMar 23, 2023 12:31 ET
Jefferies Downgrades TCR2 Therapeutics to Underperform, Lowers Price Target to $3
BenzingaMar 9, 2023 06:00 ET
Analysts Offer Insights on Healthcare Companies: TCR2 Therapeutics (TCRR) and Nurix Therapeutics (NRIX)
TipRanksMar 9, 2023 03:46 ET
Truist Securities Downgrades TCR2 Therapeutics to Hold, Lowers Price Target to $3
BenzingaMar 8, 2023 09:45 ET
Truist Securities Downgrades TCR2 Therapeutics to Hold From Buy, Cuts Price Target to $3 From $8
MT NewswiresMar 7, 2023 14:34 ET
Wedbush Lowers TCR2 Therapeutics' Price Target to $2.18 From $4 on Heels of Adaptimmune Merger Announcement, Keeps Neutral Rating
MT NewswiresMar 7, 2023 07:34 ET
TCR2 Therapeutics (TCRR) Was Downgraded to a Hold Rating at H.C. Wainwright
TipRanksMar 7, 2023 06:21 ET
SVB Securities Keeps Their Hold Rating on TCR2 Therapeutics (TCRR)
TipRanksJan 8, 2023 23:20 ET
Piper Sandler Adjusts Price Target on TCR2 Therapeutics to $10 From $8, Maintains Overweight Rating
MT NewswiresJan 6, 2023 09:45 ET
TCR2 Therapeutics Analyst Ratings
Benzinga Analyst RatingsJan 6, 2023 06:38 ET
Piper Sandler Maintains Overweight on TCR2 Therapeutics, Raises Price Target to $10
Benzinga Real-time NewsJan 6, 2023 06:38 ET
Mizuho Securities Remains a Buy on TCR2 Therapeutics (TCRR)
TipRanksJan 5, 2023 16:50 ET
TCR2 Therapeutics Analyst Ratings
Benzinga Analyst RatingsJan 5, 2023 04:34 ET
EF Hutton Initiates Coverage On TCR2 Therapeutics With Hold Rating, Announces Price Target of $2
Benzinga Real-time NewsJan 5, 2023 04:33 ET
HC Wainwright Trims Price Target on TCR2 Therapeutics to $13 From $14, Maintains Buy Rating
MT NewswiresNov 21, 2022 07:50 ET
TCR2 Therapeutics Analyst Ratings
Benzinga Analyst RatingsNov 21, 2022 06:42 ET
HC Wainwright & Co. Maintains Buy on TCR2 Therapeutics, Lowers Price Target to $13
Benzinga Real-time NewsNov 21, 2022 06:42 ET
No Data
No Data